NM600

NM600 is a small molecule **alkylphosphocholine analog** engineered as a tumor-targeting agent for use in targeted radionuclide therapy and imaging. When radiolabeled with therapeutic radioisotopes such as ^90Y (yttrium-90) or ^177Lu (lutetium-177), NM600 selectively accumulates in malignant cells due to its affinity for lipid rafts (glycosphingolipid- and cholesterol-rich membrane microdomains), which are markedly overexpressed in cancerous tissues. This receptor-independent targeting mechanism enables NM600 to deliver localized radiation to tumors, thereby inhibiting tumor growth and extending survival in preclinical cancer models, including T-cell non-Hodgkin’s lymphoma and triple-negative breast cancer. Radiolabeled NM600 can also be used with PET imaging (^86Y) in a theranostic approach to estimate dosimetry and guide therapy. Toxicity assessments in animal models show that NM600-based radiopharmaceuticals are generally well tolerated, with bone marrow as the main dose-limiting organ[1][2][3].